Conditions: Pancreatic Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 1
Healthy volunteers: no

Brief summary:
A phase 2 study combining pertuzumab with erlotinib for patients with gemcitabine refractory pancreatic adenocarcinoma

Detailed description:
A single-institution, single-arm phase 2 study investigating pertuzumab and erlotinib as a palliative regimen in the treatment of locally-advanced or metastatic pancreatic adenocarcinoma.

Arms:
arm 1: Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks

Erlotinib hydrochloride 150 mg/day by mouth

Interventions: intervention 1: Pertuzumab intervention 2: Erlotinib
Intervention descriptions: intervention 1: iv, 840 mg, 420 mg intervention 2: PO, 150 mg

Protocol document: